Amgen, Inc. - SWOT, Strategy and Corporate Finance Report
Published: December 2012 · Publisher: MarketLine
Amgen, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc.
- Description
- Table of Contents
- Ask a Question
Amgen, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company.
Features:
- Detailed information on Amgen, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Amgen, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Amgen, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Amgen, Inc.
- Intelligence on Amgen, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Amgen, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Amgen (or ‘the company’) is a leading biotechnology company engaged in the discovery, development, manufacture, and marketing of innovative human therapeutics. The company mainly focuses in the areas of cancer, kidney disease, rheumatoid arthritis and other serious illnesses. It primarily operates in the US where it is headquartered in Thousand Oaks, California. Amgen employed 17,800 people as of December 31, 2011. The company recorded revenues of $15,582 million during the financial year ended December 2011 (FY2011), an increase of 3.5% over FY2010. The operating profit of the company was $4,312 million in FY2011, a decrease of 22.2% over FY2010. The net profit was $3,683 million in FY2011, a decrease of 20.4% over FY2010.
Reasons to Purchase:
- Gain understanding of Amgen, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Amgen, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Amgen, Inc.’s business structure, strategy and prospects
Features:
- Detailed information on Amgen, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Amgen, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Amgen, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Amgen, Inc.
- Intelligence on Amgen, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Amgen, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Amgen (or ‘the company’) is a leading biotechnology company engaged in the discovery, development, manufacture, and marketing of innovative human therapeutics. The company mainly focuses in the areas of cancer, kidney disease, rheumatoid arthritis and other serious illnesses. It primarily operates in the US where it is headquartered in Thousand Oaks, California. Amgen employed 17,800 people as of December 31, 2011. The company recorded revenues of $15,582 million during the financial year ended December 2011 (FY2011), an increase of 3.5% over FY2010. The operating profit of the company was $4,312 million in FY2011, a decrease of 22.2% over FY2010. The net profit was $3,683 million in FY2011, a decrease of 20.4% over FY2010.
Reasons to Purchase:
- Gain understanding of Amgen, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Amgen, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Amgen, Inc.’s business structure, strategy and prospects
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Company Snapshot
Amgen, Inc.: Company Overview
Amgen, Inc.: Overview and Key Facts
Amgen, Inc.: Overview
Amgen, Inc.: Key Facts
Amgen, Inc.: Key Employees
Amgen, Inc.: Key Employee Biographies
Amgen, Inc.: Major Products and Services
Amgen, Inc.: Company History
Amgen, Inc.: Management Statement
Amgen, Inc.: Locations and Subsidiaries
Amgen, Inc.: Key Competitors
Amgen, Inc.: Company Analysis
Amgen, Inc.: Business Description
Amgen, Inc.: SWOT Analysis
Amgen, Inc.: SWOT Overview
Amgen, Inc.: Strengths
Amgen, Inc.: Weaknesses
Amgen, Inc.: Opportunities
Amgen, Inc.: Threats
Amgen, Inc.: Corporate Financial Deals Activity
Amgen, Inc.: Financial Deals Overview
Amgen, Inc.: Targets and Partners
Amgen, Inc.: Top Deals 2009 - 2013YTD*
Amgen, Inc.: Advisors
Amgen, Inc.: Top Legal Advisors
Amgen, Inc.: Top Financial Advisors
Amgen, Inc.: Mergers and Acquisitions
Amgen, Inc.: Partnership
Amgen, Inc.: Divestments
Amgen, Inc.: Recent Developments
Amgen, Inc.: News and Events Summary
Amgen, Inc.: Business Expansion
Amgen, Inc.: Contracts
Amgen, Inc.: Corporate Governance
Amgen, Inc.: Financial Performance
Amgen, Inc.: Research & Development
Amgen, Inc.: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: Amgen, Inc.: Key Facts
Table 2: Amgen, Inc.: Key Employees
Table 4: Amgen, Inc.: Key Competitors
Table 5: Amgen, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 6: Amgen, Inc.: M&A Activity by Geography (TTM*)
Table 7: Amgen, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 8: Amgen, Inc.: M&A Average Deal Size - Value (US$m)
Table 9: Amgen, Inc.: Targets and Partners
Table 10: Amgen, Inc.: Top Deals 2009 - 2013YTD*
Table 11: Amgen, Inc.: Legal Advisor Ranking by Value (US$m)
Table 12: Amgen, Inc.: Financial Advisor Ranking by Value (US$m)
Table 13: Amgen, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Table 14: Amgen, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Table 15: Amgen, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 16: Amgen, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 17: Amgen, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 18: Amgen, Inc.: Divestments by Geography (2009 - YTD*2013)
Table 19: Amgen, Inc.: News and Events Summary
Table 20: Amgen, Inc.: Business Expansion
Table 21: Amgen, Inc.: Contracts
Table 22: Amgen, Inc.: Corporate Governance
Table 23: Amgen, Inc.: Financial Performance
Table 24: Amgen, Inc.: Research & Development
Table 25: Amgen, Inc.: Strategy and Operations
List of Figures
Figure 1: Amgen, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Amgen, Inc.: M&A Activity by Geography (TTM*)
Figure 3: Amgen, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 4: Amgen, Inc.: M&A Average Deal Size - Value (US$m)
Figure 5: Amgen, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 6: Amgen, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Figure 7: Amgen, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 8: Amgen, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 9: Amgen, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 10: Amgen, Inc.: Divestments by Geography (2009 - YTD*2013)
Amgen, Inc.: Company Overview
Amgen, Inc.: Overview and Key Facts
Amgen, Inc.: Overview
Amgen, Inc.: Key Facts
Amgen, Inc.: Key Employees
Amgen, Inc.: Key Employee Biographies
Amgen, Inc.: Major Products and Services
Amgen, Inc.: Company History
Amgen, Inc.: Management Statement
Amgen, Inc.: Locations and Subsidiaries
Amgen, Inc.: Key Competitors
Amgen, Inc.: Company Analysis
Amgen, Inc.: Business Description
Amgen, Inc.: SWOT Analysis
Amgen, Inc.: SWOT Overview
Amgen, Inc.: Strengths
Amgen, Inc.: Weaknesses
Amgen, Inc.: Opportunities
Amgen, Inc.: Threats
Amgen, Inc.: Corporate Financial Deals Activity
Amgen, Inc.: Financial Deals Overview
Amgen, Inc.: Targets and Partners
Amgen, Inc.: Top Deals 2009 - 2013YTD*
Amgen, Inc.: Advisors
Amgen, Inc.: Top Legal Advisors
Amgen, Inc.: Top Financial Advisors
Amgen, Inc.: Mergers and Acquisitions
Amgen, Inc.: Partnership
Amgen, Inc.: Divestments
Amgen, Inc.: Recent Developments
Amgen, Inc.: News and Events Summary
Amgen, Inc.: Business Expansion
Amgen, Inc.: Contracts
Amgen, Inc.: Corporate Governance
Amgen, Inc.: Financial Performance
Amgen, Inc.: Research & Development
Amgen, Inc.: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: Amgen, Inc.: Key Facts
Table 2: Amgen, Inc.: Key Employees
Table 4: Amgen, Inc.: Key Competitors
Table 5: Amgen, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 6: Amgen, Inc.: M&A Activity by Geography (TTM*)
Table 7: Amgen, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 8: Amgen, Inc.: M&A Average Deal Size - Value (US$m)
Table 9: Amgen, Inc.: Targets and Partners
Table 10: Amgen, Inc.: Top Deals 2009 - 2013YTD*
Table 11: Amgen, Inc.: Legal Advisor Ranking by Value (US$m)
Table 12: Amgen, Inc.: Financial Advisor Ranking by Value (US$m)
Table 13: Amgen, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Table 14: Amgen, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Table 15: Amgen, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 16: Amgen, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 17: Amgen, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 18: Amgen, Inc.: Divestments by Geography (2009 - YTD*2013)
Table 19: Amgen, Inc.: News and Events Summary
Table 20: Amgen, Inc.: Business Expansion
Table 21: Amgen, Inc.: Contracts
Table 22: Amgen, Inc.: Corporate Governance
Table 23: Amgen, Inc.: Financial Performance
Table 24: Amgen, Inc.: Research & Development
Table 25: Amgen, Inc.: Strategy and Operations
List of Figures
Figure 1: Amgen, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Amgen, Inc.: M&A Activity by Geography (TTM*)
Figure 3: Amgen, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 4: Amgen, Inc.: M&A Average Deal Size - Value (US$m)
Figure 5: Amgen, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 6: Amgen, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Figure 7: Amgen, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 8: Amgen, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 9: Amgen, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 10: Amgen, Inc.: Divestments by Geography (2009 - YTD*2013)
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.